Systems and solutions for medical applications


Do you already have this product?
Name* :
Family Name* :
Country* :
E-mail* :
Message* :
Type the code from the image

I have read and approved your Privacy Policy (View)
accept not accept
I agree to receive, from time to time, information on DEKA products, services and events.
accept not accept
Pulse and Wavelength: the Perfect Synergy for Laserlipolysis®
Skin Tightening
Body Shaping & Cellulite
Nd:YAG Gradient Pulse - 1064nm


  Where DEKA makes the difference
Laserlipolisi®: Scientific Innovation Sees the Light at Deka

DEKA is the first company in the world to have invented an innovative method for removing localised fat deposits: Laserlipolisi®. Through the exploitation of a specific 1064 nm wavelength and an exclusive pulse shape, DEKA has perfected a minimally invasive laser treatment that stands out from the rest. This unparalleled achievement stems from over ten years of research, publications, and case studies
Laser-Assisted Liposuction
Axillary Hyperhydrosis and Osmidrosis
Removal of Lipomas
Filler Granulomas
  1. Innovative solution based on years of experience
  2. Exclusive Gradient Pulse formula
  3. From Liposculpture to a whole new range of applications

The Smartlipo® has been my greatest ally for years. Laserlipolysis® created new and important opportunities for my patients This is the most innovative and safest technique for anyone who wants to permanently change targeted body areas by removing excess fat and reducing flabbiness while improving skin tone. Now especially, Laserlipolysis® enables me to give patients what they really want:  minimally invasive treatments with very short recovery times. The procedure is carried out under local anaesthetic and patients can immediately return to their daily activities thereafter. Over the years, the safety, versatility, and special features of the Smartlipo® system have enabled me to explore new areas of application, experimenting, for example, the reduction of bags under eyes and the reabsorption of filler granulomas.

Nicola Zerbinati, MD
Department of Clinical and Biological Science
University of Insubria – Varese, Italy